AXON (Axon Enterprise) is a profitable, large-cap public-safety technology leader growing revenue above 30% year over year, while SEER (Seer, Inc.) is a small-cap life-sciences company still generating modest revenue and operating at a loss. Axon has raised its full-year revenue outlook in recent quarters, but its shares remain roughly 25% lower year-to-date and about 43% lower over the trailing year despite strong fundamentals.
AVXL is a clinical-stage biopharmaceutical company whose shares have fallen sharply in recent quarters after a European regulatory setback and governance disclosures, leaving the stock trading near its cash value. AXON is a profitable public-safety technology leader with strong recurring revenue growth, though its shares have also pulled back materially from their 2025 peak on valuation and margin concerns.
Axon Enterprise (AXON) is a large-cap public safety technology leader (market capitalization near $34.6 billion) with profitable, recurring revenue growth, while Codexis (CDXS) is a micro-cap biotechnology firm (market capitalization near $140 million) still investing ahead of scaled commercial revenue. Despite roughly 30%+ revenue growth, AXON has been under pressure recently — down about 43% over the past year — as a premium valuation reset amid the broader software sell-off.
ALXO is a clinical-stage, pre-revenue immuno-oncology biotech, while AXON is a profitable, fast-growing public-safety technology company — a stark contrast in business maturity and risk profile. Axon generates strong recurring revenue, with annual recurring revenue (ARR) up 39% to roughly $1.6 billion, while ALX Oncology reports no product revenue and relies on cash runway and clinical catalysts.
AXON (Axon Enterprise) is a profitable, large-cap public-safety technology leader, while OCGN (Ocugen) is a clinical-stage biotechnology company with no approved products and minimal revenue. AXON has recently regained short-term momentum following its Body 5 camera launch and a raised 2026 revenue outlook, even as the stock remains well below its 2025 highs.
Allogene Therapeutics (ALLO) is a clinical-stage biotech with no marketed product, while Axon Enterprise (AXON) is a profitable public-safety technology leader with rapid revenue growth. ALLO's near-term story hinges on clinical trial catalysts, particularly the ALPHA3 study and a fourth-quarter 2026 data update for its autoimmune program.
ASTS and RKLB are both high-growth, pre-profit space companies, but they compete in different niches: satellite-based cellular broadband versus launch services and space systems. Both stocks have pulled back sharply from their highs in recent months, with ASTS trading near a 52-week low and RKLB down roughly 60–65% from its mid-2026 peak.
RDW and VOYG both operate in the space and defense technology arena, but they emphasize different ends of that market: Redwire leans on space hardware and uncrewed aerial systems (UAS), while Voyager spans defense, national security, and commercial space stations. Both companies are growing revenue rapidly and building record backlogs, yet both remain unprofitable, making relative performance a story about momentum and execution rather than current earnings.
Different space businesses: PL (Planet Labs) sells Earth-observation imagery and data, while RKLB (Rocket Lab) provides launch services and spacecraft components. Both pulled back sharply: Each stock has declined roughly 25% or more in recent weeks and trades well below its 52-week high following a broader cooling in space-sector sentiment.
Voyager Technologies (VOYG) shares fell roughly 12% over the past 30 days, from about $31.35 to near $27.45 in the latest session, driven primarily by a convertible-note offering and related dilution concerns. The sharpest move came in late September, when Voyager announced a $350 million private offering of 0% convertible senior notes due 2032, sending the stock down about 16% in a single session.
Draganfly shares fell roughly 31% over the trailing 30 days, from a close near $5.35 to about $3.69, as the stock gave back a sharp late-summer rally. The decline followed a surge above $6 in late August and early September driven by a Canadian Armed Forces drone contract and new strategic investment.
Boeing shares declined roughly 13.5% over the last 30 days, falling from about $198 to near $171. The pullback intensified after third-quarter 2026 results, when an adjusted loss of $0.34 per share missed the roughly $0.21 consensus estimate.
BA is down -9.05% to $171.26 during regular trading, after slipping roughly -2.5% in premarket following its Q3 earnings release. The primary catalyst was a wider-than-expected Q3 loss: core EPS of -$0.34 versus the -$0.21 consensus, with revenue of $24.19B.
VOYG is trading up +11.34% during regular market hours, climbing from a prior close of $24.78 to roughly $27.59. Primary catalyst is bullish momentum from its Interstellar Lab ISS mission-management contract (BioPod EDEN) plus the Griffin-1 lunar lander completing acceptance testing.
SAIQ has risen roughly 264% from its first-day closing price of $1.85 to about $6.73, though the move has been exceptionally volatile. The shares only began trading on October 2, 2026, after completing a business combination with Columbus Acquisition Corp., so its 30-day record spans nearly its entire public history.
SAIQ gained +9.97% in Monday's regular session, closing at $6.73 from a $6.12 prior close, and extended higher in overnight/premarket trading. Primary catalyst: SEALSQ signed a $15M binding LOI for capacity on 12 WISeSat satellites, marking the company's first major commercial contract.
Defense backlog anchors visibility: A record backlog of roughly $136.5 billion provides multi-year revenue clarity across Marine Systems, Combat Systems, Aerospace, and Technologies, reducing near-term demand uncertainty. Submarine and naval programs are the core growth engine: The Columbia- and Virginia-class submarine franchises, supported by a multi-billion-dollar U.S. Navy shipbuilding plan, underpin Marine Systems momentum.
The central stock price target is $400 , the arithmetic mean of roughly 14 recently updated, individually attributable analyst targets (about $403), rounded to a clean level. With the latest price near $357 , reaching $400 implies roughly 12% upside — a modest move for a large-cap industrial.
General Dynamics shares are trading near $356, up roughly 5.8% over the trailing 30 days after rebounding from an early-October low around $322. The stock remains below its late-July levels near $393 and its 52-week high of $400, reflecting a still-soft broader defense tape.
Boeing reported third-quarter 2026 revenue of $24.2 billion , up 4% from the same period a year earlier and roughly in line with analyst expectations. Net loss narrowed sharply to $116 million , or $0.26 per share, compared with a $5.3 billion loss a year ago, when the 777X certification delay drove a large charge.